Novo Tests Lower Doses of Wegovy Pill
Novo Nordisk has launched a late stage clinical trial for its Wegovy pill to determine the lowest effective dose for weight loss. The study runs through 2028 and evaluates oral semaglutide against a placebo.
Insights:
Novo Nordisk started a late-stage trial on August 12 to test lower doses of its oral Wegovy pill, aiming to identify the minimum effective weight-loss dose. The study launched as the Danish drugmaker faces intensifying competition in the obesity drug market, which United States rival Eli Lilly also targets. The obesity therapeutics market is projected to surpass $100 billion annually by 2030.
